Crucell

Leiden, The Netherlands, August 17, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center of the US Navy to construct AdVac®-based vaccines against anthrax and plague and test them in non-human primates. Like Ebola and Marburg, anthrax and plague are among the so-called ´Category A´ agents, which are considered by the Centers for Disease Control and Prevention (CDC) and the World Health Organiz…

Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron Leiden, The Netherlands, August 16, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6® cell line for use in the manufacturing of Chiron´s prophylactic hepatitis C vaccine, which is currently in phase I clinical trials. F…